References:
- Bakst RL, Campbell BA, Pinnix CC. PET Guided Therapy for Early Stage
Hodgkin Lymphoma: Are We Positive About a Negative Interim Scan? Int J
Radiat Oncol Biol Phys 2020;107(1):12-17.
- Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA,
Attarbaschi A, et al. Response-adapted omission of radiotherapy and
comparison of consolidation chemotherapy in children and adolescents
with intermediate-stage and advanced-stage classical Hodgkin lymphoma:
a titration study with an open-label, embedded, multinational,
non-inferiority, randomised controlled trial. Lancet Oncol
2022;23(1):125.
- Arora RS, Bakhshi S. Indian Pediatric Oncology Group (InPOG) –
Collaborative research in India comes of age. Pediatr Hematol Oncol
2016;1(1):13–17.
- Arora RS, Mahajan A, Dinand V, Kalra M, Jain S, Taluja A, et al.
InPOG-HL-15-01 - Challenges and lessons learnt in setting up the first
collaborative multicentre prospective clinical trial in childhood
cancer in India. Pediatr Hematol Oncol 2020;5(4):166-170.
- Mahajan A, Singh M, Bakhshi S, Jain S, Radhakrishnan V, Verma N, et
al. Treating early‐stage Hodgkin lymphoma in resource‐limited
settings: InPOG‐HL‐15‐01 experience. Pediatr blood cancer
2021;68(10):1-9.
- Jain S, Bakhshi S, Seth R, Verma N, Singh M, Mahajan A, et al. Risk
based and response adapted radiation therapy for children and
adolescents with newly diagnosed advanced stage Hodgkin lymphoma
treated with ABVD chemotherapy: a report from the Indian pediatric
oncology group study InPOG-HL-15-01. Leuk. Lymphoma
;ahead-of-print(ahead-of-print):1-8.
- Lopez-Alonso R, Qi S, Mashiach T, Weiler-Sagie M, Yahalom J, Dann EJ.
The presence of a bulky mediastinal mass of 7 cm or greater in
diameter confers an adverse prognosis to patients with advanced
Hodgkin lymphoma in case of negative interim PET/CT. Leuk. Lymphoma
2021;62(6):1313.
- Trotman J, Barrington SF. The role of PET in first-line treatment of
Hodgkin lymphoma. Lancet Haematol 2021;8(1):e67-e79.
- Panebianco M, Bagni O, Cenfra N, Mecarocci S, Ortu La Barbera E,
Filippi L, et al. Comparison of 18F FDG PET-CT AND CECT in
pretreatment staging of adults with Hodgkin lymphoma. Leuk Res
2019;76:48-52.
- Gómez León N, Delgado-Bolton R, del Campo del Val, Lourdes, Cabezas B,
Arranz R, García M, et al. Multicenter Comparison of Contrast-Enhanced
FDG PET/CT and 64-Slice Multi–Detector-Row CT for Initial Staging and
Response Evaluation at the End of Treatment in Patients with Lymphoma.
Clin Nucl Med 2017;42(8):595-602.
- Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M,
Mueller SP, et al. Role of Imaging in the Staging and Response
Assessment of Lymphoma: Consensus of the International Conference on
Malignant Lymphomas Imaging Working Group. J Clin Oncol
2014;32(27):3048-3058.
- Voltin C, Mettler J, Grosse J, Dietlein M, Baues C, Schmitz C, et al.
FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An
Updated Overview. Cancer 2020;12(3):601.
- Parambil BC, Narula G, Prasad M, Shah S, Shet T, Shridhar E, et al.
Clinical profile and outcome of classical Hodgkin lymphoma treated
with a risk‐adapted approach in a tertiary cancer center in India.
Pediatr Blood Cancer 2020;67(2):1-7.
- Palayullakandi A, Trehan A, Jain R, Kumar R, Mittal BR, Kapoor R, et
al. Retrospective single-center experience with OEPA/COPDAC and PET-CT
based strategy for pediatric Hodgkin lymphoma in a LMIC setting.
Pediatr Hematol Oncol 2022;10:1-13
- Totadri, S., Radhakrishnan, V., Ganesan, T.S., Ganesan, P., Kannan,
K., Lakshmipathy, K.M., Selvaluxmy, G., & Sagar, T.G. Can
Radiotherapy Be Omitted in Children With Hodgkin Lymphoma Who Achieve
Metabolic Remission on Interim Positron Emission Tomography?
Experience of a Tertiary Care Cancer Referral Center. J Glob Oncol
2018;4:1-7.
- Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, et al.
Response‐adapted therapy for the treatment of children with newly
diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the
Children’s Oncology Group. Br J Haematol 2019;187(1):39-48.
- Wolden SL, Lu Chen, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et
al. Long-Term Results of CCG 5942: A Randomized Comparison of
Chemotherapy With and Without Radiotherapy for Children With Hodgkin
Lymphoma—A Report From the Children’s Oncology Group. J Clin Oncol
2012;30(26):3174-3180.
- Seshachalam A, Karpurmath SV, Rathnam K, Raman SG, Janarthinakani M,
Prasad K. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome
in Hodgkin Lymphoma? Real-World Evidence. J Glob Oncol 2019;(5):1-13.
- Shaikh PM, Alite F, Pugliese N, Picardi M, Vargo JA. Consolidation
radiotherapy following positron emission tomography complete response
in early-stage Hodgkin lymphoma: a meta-analysis. Leuk. Lymphoma 2020
;61(7):1610-1617.
- Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, et
al. Randomized comparison of consolidation radiation versus
observation in bulky Hodgkin lymphoma with post-chemotherapy negative
positron emission tomography scans. Leuk. Lymphoma
2007;48(9):1721-1727.
- Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P,
et al. Results of a Trial of PET-Directed Therapy for Early-Stage
Hodgkin Lymphoma. N Engl J Med 2015;372(17):1598-1607.
- André M, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al.
Early Positron Emission Tomography Response-Adapted Treatment in Stage
I and II Hodgkin Lymphoma: Final Results of the Randomized
EORTC/LYSA/FIL H10 Trial. J Clin Oncol 2017;35(16):1786.
- Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al.
Positron emission tomography-guided treatment in early-stage favorable
Hodgkin lymphoma: Final results of the international, randomized phase
III HD16 trial by the German Hodgkin Study Group. J Clin Oncol
2019;37(31):2835-2845.
- Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, et
al. Five-year follow-up of SWOG S0816: limitations and values of a
PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood
2019;134(15):1238-1246.
- Borchmann P, Plütschow AJ, Kobe C, Greil R, Meissner J, Topp MS, et
al. PET-Guided omission of radiotherapy in early-stage unfavourable
Hodgkin lymphoma: a multicentre, open-label, randomised, phase 3
trial. Lancet Oncol 2021;22(2):223.